A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Exclusion Criteria

• •Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3) nodal involvement
• •Has received any prior treatment, including radiation, systemic therapy,and/or definitive surgery for currently diagnosed breast cancer
• •Has undergone excisional biopsy of the primary tumor, axillary lymph node dissection, and/or axillary sentinel lymph node biopsy prior to study treatment.
• •Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
• •Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137).
• •Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC).
• •Received prior treatment with a topoisomerase I inhibitor-containing ADC.
• •Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
• •Known additional malignancy that is progressing or has required active treatment within the past 5 years.
• •Uncontrolled systemic disease.
• •History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.